Abstract Background Unresolved retinal fluid and high injection burden are major challenges for patients with neovascular age-related macular degeneration. Brolucizumab addresses these challenges by providing robust vision gains and superior fluid resolution. with the potential for longer treatment intervals. Brolucizumab has been associated with adverse events of retinal vasculitis a... https://www.roneverhart.com/